Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial

Stephen B Freedman, Sarah Williamson-Urquhart, Suzanne Schuh, Philip M Sherman, Ken J Farion, Serge Gouin, Andrew R Willan, Ron Goeree, David W Johnson, Karen Black, David Schnadower, Marc H Gorelick, Pediatric Emergency Research Canada (PERC) Gastroenteritis Study Group, Stephen B Freedman, Sarah Williamson-Urquhart, Suzanne Schuh, Philip M Sherman, Ken J Farion, Serge Gouin, Andrew R Willan, Ron Goeree, David W Johnson, Karen Black, David Schnadower, Marc H Gorelick, Pediatric Emergency Research Canada (PERC) Gastroenteritis Study Group

Abstract

Background: The burden of acute gastroenteritis on children and their families continues to be enormous. Probiotics, defined as viable microbial preparations that have a beneficial effect on the health of the host, represent a rapidly expanding field. Although clinical trials in children with gastroenteritis have been performed, most have significant flaws, and guidelines do not consistently endorse their use.

Methods/design: PROGUT is a randomized, placebo-controlled, double-blind, five-center, Canadian, emergency department trial. Children aged 3 months to 48 months who present between November 2013 and June 2017 with <72 hours of gastroenteritis symptoms will be assessed for eligibility. A total of 886 children will be randomized (1:1 allocation via an internet based, third party, randomization service) to receive 5 days of a combination probiotic agent (Lactobacillus rhamnosus and L. helveticus) or placebo. All participants, caregivers, and outcome assessors will be blinded to group assignment. The study includes three key outcomes: 1) clinical - the development of moderate to severe disease following an emergency department (ED) evaluation that employs a validated clinical score (Modified Vesikari Scale); 2) safety - side effect; and 3) mechanism - fecal secretory immunoglobulin A levels.

Discussion: Definitive data are lacking to guide the clinical use of probiotics in children with acute gastroenteritis. Hence, probiotics are rarely prescribed by North American physicians. However, the following current trends obligate an urgent assessment: 1) probiotics are sold as food supplements, and manufacturers can encourage their use while their relevance has yet to be established; 2) North American and European government agencies remain concerned about their value and safety; 3) some institutions are now recommending the routine use of probiotics; and 4) parents of affected children are often providing probiotics. With probiotic consumption increasing in the absence of solid evidence, there is a need to conduct this definitive trial to overcome the limitations of prior work in this field.

Trial registration: ClinicalTrials.gov: NCT01853124; first registered 9 May 2013.

Trial registration: ClinicalTrials.gov NCT01773967 NCT01853124.

References

    1. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States–unspecified agents. Emerg Infect Dis. 2011;17:16–22. doi: 10.3201/eid1701.P21101.
    1. Jones TF, McMillian MB, Scallan E, Frenzen PD, Cronquist AB, Thomas S, Angulo FJ. A population-based estimate of the substantial burden of diarrhoeal disease in the United States; FoodNet, 1996–2003. Epidemiol Infect. 2007;135:293–301. doi: 10.1017/S0950268806006765.
    1. Senecal M, Brisson M, Lebel MH, Yaremko J, Wong R, Gallant LA, Garfield HA, Ableman DJ, Ward RL, Sampalis JS, Mansi JA. group Ms. Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): a prospective community-based study. Can J Infect Dis Med Microbiol. 2008;19:397–404.
    1. Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW. Substantial morbidity for hospitalized children with community-acquired rotavirus infections, 2005–2007 IMPACT surveillance in Canadian hospitals. Pediatr Infect Dis J. 2010;29:879–882. doi: 10.1097/INF.0b013e3181e20c94.
    1. Mast TC, DeMuro-Mercon C, Kelly CM, Floyd LE, Walter EB. The impact of rotavirus gastroenteritis on the family. BMC Pediatr. 2009;9:11. doi: 10.1186/1471-2431-9-11.
    1. Salminen S, Ouwehand A, Benno Y, Lee YK. Probiotics: how should they be defined? Trend Food Sci Technol. 1999;10:107–110. doi: 10.1016/S0924-2244(99)00027-8.
    1. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109:678–684. doi: 10.1542/peds.109.4.678.
    1. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001;33(Suppl 2):S17–S25.
    1. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25:871–881. doi: 10.1111/j.1365-2036.2007.03282.x.
    1. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002;47:2625–2634. doi: 10.1023/A:1020501202369.
    1. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11:CD003048.
    1. Das RR. Should probiotics be used in the treatment of acute childhood diarrhea? J Clin Gastroenterol. 2012;46:526–527. doi: 10.1097/MCG.0b013e31824b239f.
    1. Weizman Z. Probiotics use in childhood acute diarrhea: a web-based survey. J Clin Gastroenterol. 2011;45:426–428. doi: 10.1097/MCG.0b013e3181ef375d.
    1. D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ (Clinical Research Ed) 2002;324:1361. doi: 10.1136/bmj.324.7350.1361.
    1. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;16:658–672. doi: 10.1128/CMR.16.4.658-672.2003.
    1. Li ST, Klein EJ, Tarr PI, Denno DM. Parental management of childhood diarrhea. Clin Pediatr (Phila) 2009;48:295–303.
    1. Vernacchio L, Vezina RM, Mitchell AA, Lesko SM, Plaut AG, Acheson DW. Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J. 2006;25:2–7. doi: 10.1097/01.inf.0000195623.57945.87.
    1. Freedman SB, Gouin S, Bhatt M, Black KJ, Johnson D, Guimont C, Joubert G, Porter R, Doan Q, van Wylick R, Schuh S, Atenafu E, Eltorky M, Cho D, Plint A. Prospective assessment of practice pattern variations in the treatment of pediatric gastroenteritis. Pediatrics. 2011;127:e287–e295. doi: 10.1542/peds.2010-2214.
    1. Freedman SB, Sivabalasundaram V, Bohn V, Powell EC, Johnson DW, Boutis K. The treatment of pediatric gastroenteritis: a comparative analysis of pediatric emergency physicians’ practice patterns. Acad Emerg Med. 2011;18:38–45. doi: 10.1111/j.1553-2712.2010.00960.x.
    1. Katan MB. Why the European Food Safety Authority was right to reject health claims for probiotics. Benef Microbes. 2012;3:85–89. doi: 10.3920/BM2012.0008.
    1. Vero V, Gasbarrini A. The EFSA health claims ‘learning experience’. Int J Food Sci Nutr. 2012;63(Suppl 1):14–16.
    1. Flynn A. Scientific substantiation of health claims in the EU. Proc Nutr Soc. 2012;71:120–126. doi: 10.1017/S0029665111003168.
    1. Heimbach JT. Health-benefit claims for probiotic products. Clin Infect Dis. 2008;46(Suppl 2):S122–S124. discussion S144-S151.
    1. Markets and Markets. Global Probiotics Market Worth US$32.6 Billion by 2014. Available at: Accessed May 9, 2014. Wilmington, DE.
    1. Coppens P, da Silva MF, Pettman S. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety. Toxicology. 2006;221:59–74. doi: 10.1016/j.tox.2005.12.022.
    1. Saldanha LG. US Food and Drug Administration regulations governing label claims for food products, including probiotics. Clin Infect Dis. 2008;46(Suppl 2):S119–S121.
    1. von Wright A. Regulating the safety of probiotics–the European approach. Curr Pharm Des. 2005;11:17–23. doi: 10.2174/1381612053382322.
    1. Parker MW, Schaffzin JK, Lo Vecchio A, Yau C, Vonderhaar K, Guiot A, Brinkman WB, White CM, Simmons JM, Gerhardt WE, Kotagal UR, Conway PH. Rapid adoption of Lactobacillus rhamnosus GG for acute gastroenteritis. Pediatrics. 2013, Mar;131(Suppl 1):S96–S102.
    1. Guyatt G, Montori V, Devereaux PJ, Schunemann H, Bhandari M. Patients at the center: in our practice, and in our use of language. ACP J Club. 2004;140:A11–A12.
    1. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol. 2008;42(Suppl 2):S53–S57.
    1. Vandenplas Y, Salvatore S, Vieira M, Devreker T, Hauser B. Probiotics in infectious diarrhoea in children: are they indicated? Eur J Pediatr. 2007;166:1211–1218. doi: 10.1007/s00431-007-0497-9.
    1. Coffin SE, Elser J, Marchant C, Sawyer M, Pollara B, Fayorsey R, Nelson L, Lawley D, Goveia M, Stek J, Hille D, DiNubile MJ. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr Infect Dis J. 2006;25:584–589. doi: 10.1097/01.inf.0000220251.27595.74.
    1. Szymanski H, Pejcz J, Jawien M, Chmielarczyk A, Strus M, Heczko PB. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains–a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:247–253. doi: 10.1111/j.1365-2036.2006.02740.x.
    1. Nixon AF, Cunningham SJ, Cohen HW, Crain EF. The effect of Lactobacillus GG on acute diarrheal illness in the pediatric emergency department. Pediatr Emerg Care. 2012;28:1048–1051. doi: 10.1097/PEC.0b013e31826cad9f.
    1. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis. 2008;46(Suppl 2):S87–S91. discussion S144-S151.
    1. Sarker SA, Fuchs GJ. In: Proboitics in Pediatric Medicine. Michail S, Sherman PM, editor. Totowa, NJ: Humana Press; 2009. The role of probiotics in the treatment and prevention of infectious diarrhea in children.
    1. World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers. WHO Press: Geneva, Switzerland; 2005. (4th revision).
    1. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, Rincon C, Hortal J, Pelaez T. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625–1634. doi: 10.1086/429916.
    1. Riquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, Arrese M, Labarca JA. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003;36:41–43. doi: 10.1097/00004836-200301000-00013.
    1. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–659. doi: 10.1016/S0140-6736(08)60207-X.
    1. Tlaskal P, Schramlova J, Kokesova A, Adamus J, Bubakova D, Kocnarova N, Kopecka K, Muckova M, Pacovska J, Sladkova E. Probiotics in the treatment of diarrheal disease of viral etiology in children. NAFAS. 2005;3:25–28.
    1. Szajewska H, Setty M, Mrukowicz J, Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr. 2006;42:454–475. doi: 10.1097/01.mpg.0000221913.88511.72.
    1. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ. 2006;175:377–383. doi: 10.1503/cmaj.051603.
    1. Freedman SB, Eltorky M, Gorelick M. Pediatric Emergency Research Canada Gastroenteritis Study G Evaluation of a gastroenteritis severity score for use in outpatient settings. Pediatrics. 2010;125:e1278–e1285. doi: 10.1542/peds.2009-3270.
    1. Fruhwirth M, Heininger U, Ehlken B, Petersen G, Laubereau B, Moll-Schuler I, Mutz I, Forster J. International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection. Pediatr Infect Dis J. 2001;20:784–791. doi: 10.1097/00006454-200108000-00013.
    1. Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine. 2008;26:5798–5801. doi: 10.1016/j.vaccine.2008.08.030.
    1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Sáez-Llorens X. et al.Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. doi: 10.1056/NEJMoa052434.
    1. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–298. doi: 10.1056/NEJMoa0904797.
    1. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22:259–267. doi: 10.3109/00365549009027046.
    1. Iturriza Gomara M, Simpson R, Perault AM, Redpath C, Lorgelly P, Joshi D, Mugford M, Hughes CA, Dalrymple J, Desselberger U, Gray J. Structured surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common viral gastroenteric pathogens. Epidemiol Infect. 2008;136:23–33.
    1. Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine. 2012;30(Suppl 1):A79–A85.
    1. Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine. 2012;30(Suppl 1):A52–A60.
    1. Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012;30(Suppl 1):A24–A29.
    1. Huppertz HI, Forster J, Heininger U, Roos R, Neumann HU, Hammerschmidt T. The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr. 2008;47:363–371. doi: 10.1177/0009922807310933.
    1. Diez-Domingo J, Patrzalek M, Cantarutti L, Arnould B, Meunier J, Soriano-Gabarro M, Meyer N, Pircon JY, Holl K. The impact of childhood acute rotavirus gastroenteritis on the parents’ quality of life: prospective observational study in European primary care medical practices. BMC Pediatr. 2012;12:58. doi: 10.1186/1471-2431-12-58.
    1. Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand. 1991;80:173–180. doi: 10.1111/j.1651-2227.1991.tb11830.x.
    1. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 1997;350:1205–1209. doi: 10.1016/S0140-6736(97)05118-0.
    1. Cicek C, Karatas T, Altuglu I, Koturoglu G, Kurugol Z, Bilgic A. Comparison of ELISA with shell vial cell culture method for the detection of human rotavirus in fecal specimens. New Microbiol. 2007;30:113–118.
    1. Binka FN, Anto FK, Oduro AR, Awini EA, Nazzar AK, Armah GE, Asmah RH, Hall AJ, Cutts F, Alexander N, Brown D, Green J, Gray J, Iturriza-Gomara M. Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Trop Med Int Health. 2003;8:840–846.
    1. Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997;25:516–519. doi: 10.1097/00005176-199711000-00005.
    1. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991;88:90–97.
    1. Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Moller PL, Pedersen P, Tvede M, Weyrehter H, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J. 2002;21:411–416. doi: 10.1097/00006454-200205000-00012.
    1. Schnadower D, Tarr PI, Gorelick MH, O’Connell K, Roskind CG, Powell EC, Rao J, Bhatt S, Freedman SB. Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr. 2013;57:514–519. doi: 10.1097/MPG.0b013e31829ae5a3.
    1. Fleiss J. Statistical Methods for Rates and Proportions. 2. New York: John Wiley & Sons; 1981.
    1. Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006;354:1698–1705. doi: 10.1056/NEJMoa055119.
    1. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, Mitton C, Gouin S, Bhatt M, Joubert G, Black KJ, Turner T, Whitehouse S, Klassen TP. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med. 2009;360:2079–2089. doi: 10.1056/NEJMoa0900544.
    1. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, Ruddy RM, Malik B, Nelson KA, Bregstein JS, Brown KM, Denenberg MN, Lillis KA, Cimpello LB, Tsung JW, Borgialli DA, Baskin MN, Teshome G, Goldstein MA, Monroe D, Dean JM, Kuppermann N. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007;357:331–339. doi: 10.1056/NEJMoa071255.
    1. Scholtens PA, Alliet P, Raes M, Alles MS, Kroes H, Boehm G, Knippels LM, Knol J, Vandenplas Y. Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides. J Nutr. 2008;138:1141–1147.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir